Derivative Liabilities - Fair Value
Edwards Lifesciences Derivative Liabilities - Fair Value decreased by 70.0% to $7.60M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 27.6%, from $10.50M to $7.60M. Over 5 years (FY 2020 to FY 2025), Derivative Liabilities - Fair Value shows a downward trend with a -8.4% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
An increase in liabilities suggests unfavorable market movements for the company's hedges, while a decrease indicates a reduction in potential settlement obligations.
Detailed definition
This represents the fair value of derivative financial instruments that are currently in a liability position. These lia...
Peer comparison
Standard for energy companies; peers with similar hedging profiles will show comparable volatility in this line item.
derivative_liabilities_fair_valueHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $7.90M | $3.50M | $3.90M | $3.80M | $2.00M | $4.40M | $20.70M | $23.40M | $17.80M | $6.70M | $15.20M | $4.90M | $4.70M | $24.30M | $8.30M | $10.50M | $54.20M | $34.50M | $25.30M | $7.60M |
| QoQ Change | — | -55.7% | +11.4% | -2.6% | -47.4% | +120.0% | +370.5% | +13.0% | -23.9% | -62.4% | +126.9% | -67.8% | -4.1% | +417.0% | -65.8% | +26.5% | +416.2% | -36.3% | -26.7% | -70.0% |
| YoY Change | — | — | — | — | -74.7% | +25.7% | +430.8% | +515.8% | +790.0% | +52.3% | -26.6% | -79.1% | -73.6% | +262.7% | -45.4% | +114.3% | >999% | +42.0% | +204.8% | -27.6% |
Derivative Liabilities - Fair Value at Other Companies
Frequently Asked Questions
- What is Edwards Lifesciences's derivative liabilities - fair value?
- Edwards Lifesciences (EW) reported derivative liabilities - fair value of $7.60M in Q1 2026.
- How has Edwards Lifesciences's derivative liabilities - fair value changed year-over-year?
- Edwards Lifesciences's derivative liabilities - fair value decreased by 27.6% year-over-year, from $10.50M to $7.60M.
- What is the long-term trend for Edwards Lifesciences's derivative liabilities - fair value?
- Over 5 years (2020 to 2025), Edwards Lifesciences's derivative liabilities - fair value has grown at a -8.4% compound annual growth rate (CAGR), from $39.30M to $25.30M.
- What does derivative liabilities - fair value mean?
- The total market value of all derivative contracts that are currently resulting in a loss.